• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Paxman

47.50 SEK-2.26 %16.7. klo 18.25
Less than 1K followers

PAX

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-2.26 %
-6.86 %
-2.16 %
-11.05 %
-15.48 %
-38.47 %
+58.33 %
-16.67 %
+335.78 %

Paxman is active in scalp cooling, which is used for patients undergoing chemotherapy. The company's product Paxman Scalp Cooler is used to minimize hair loss in patients during treatment. The Scalp Cooler is a freestanding, mobile and electrically powered cooling unit that cools the patient's scalp via a cooling cap. Paxman was founded in 1996 and is headquartered in Karlshamn.

Read more
Market cap
1.11B SEK
Turnover
484.09K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
21.8.
2026

Interim report Q2'26

20.11.
2026

Interim report Q3'26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release16.07.2026 klo 17.54

DNB Carnegie Access: Paxman: CMS proposed rules – directionally positive

Paxman
Press release16.07.2026 klo 17.00

CMS Proposes Important Medicare Payment Policy Change for Mechanical Scalp Cooling

Paxman
Press release14.07.2026 klo 10.33

DNB Carnegie Access: Paxman: CIPN regulatory clearance in the EU and UK

Paxman

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release14.07.2026 klo 10.00

Paxman Expands Global Regulatory Certifications for Cryocompression Device for Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN)

Paxman
Regulatory press release22.05.2026 klo 12.05

Press release from PAXMAN AB’s 2026 Annual General Meeting

Paxman
Press release22.05.2026 klo 08.29

DNB Carnegie Access: Paxman: IBBM on track and CIPN catalyst pending – Q1 review

Paxman
Press release21.05.2026 klo 13.07

Redeye: Paxman (Q1 Initial take): In line with expectations

Paxman
Press release21.05.2026 klo 09.21

DNB Carnegie Access: Paxman: Clean beat to start the year – Q1 initial

Paxman
Regulatory press release21.05.2026 klo 08.00

PAXMAN publishes its interim report for Q1 2026

Paxman
Press release20.05.2026 klo 11.00

Invitation: Live Presentation with Richard Paxman – Q1 2026

Paxman
Press release12.05.2026 klo 12.47

Redeye: Paxman (Q1 Preview): First CPT1 quarter

Paxman
Press release30.04.2026 klo 10.06

DNB Carnegie Access: Paxman: New year, new model – Q1 preview

Paxman
Regulatory press release24.04.2026 klo 08.00

Paxman publishes the company’s annual report for 2025

Paxman
Regulatory press release20.04.2026 klo 11.00

NOTICE OF ANNUAL GENERAL MEETING IN PAXMAN AB (publ)

Paxman
Press release02.03.2026 klo 12.19

Redeye: Paxman (Q4 Review): Quarter below expectations, but IBBM development is encouraging

Paxman
Press release02.03.2026 klo 09.42

DNB Carnegie Access: Paxman: Closing the chapter on an eventful 2026 – Q4 review

Paxman
Press release27.02.2026 klo 09.49

DNB Carnegie Access: Paxman: Margin pressure reached its peak – Q4 initial comment

Paxman
Regulatory press release27.02.2026 klo 08.00

PAXMAN publishes year-end report as of 31 December 2025

Paxman
Press release23.02.2026 klo 12.30

Invitation: Live Presentation with CEO Richard Paxman – Year-end report 2025

Paxman
Press release23.02.2026 klo 11.53

DNB Carnegie Access: Paxman: Category III CPT Codes for Cryocompression secured

Paxman